These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 19474110)

  • 1. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
    O'Neill LA; Bryant CE; Doyle SL
    Pharmacol Rev; 2009 Jun; 61(2):177-97. PubMed ID: 19474110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
    Li TT; Ogino S; Qian ZR
    World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Toll-like receptors: emerging therapeutics?
    Hennessy EJ; Parker AE; O'Neill LA
    Nat Rev Drug Discov; 2010 Apr; 9(4):293-307. PubMed ID: 20380038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors: cost or benefit for cancer?
    Matijevic T; Pavelic J
    Curr Pharm Des; 2010; 16(9):1081-90. PubMed ID: 20030618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus.
    Yu SL; Chan PK; Wong CK; Szeto CC; Ho SC; So K; Yu MM; Yim SF; Cheung TH; Wong MC; Cheung JL; Yeung AC; Li EK; Tam LS
    Arthritis Res Ther; 2012 Apr; 14(2):R80. PubMed ID: 22513098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
    O'Neill LA
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases.
    Flórez-Álvarez L; Ruiz-Perez L; Taborda N; Hernandez JC
    Immunotherapy; 2020 Apr; 12(5):311-322. PubMed ID: 32237938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Toll-like receptors for treatment of SLE.
    Horton CG; Pan ZJ; Farris AD
    Mediators Inflamm; 2010; 2010():. PubMed ID: 20886024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feline pancreatic islet-like clusters and insulin producing cells express functional Toll-like receptors (TLRs).
    Franchini M; Zini E; Osto M; Jablonski K; Kaufmann K; Lutz TA; Reusch CE; Ackermann M
    Vet Immunol Immunopathol; 2010 Nov; 138(1-2):70-8. PubMed ID: 20674989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors of the ascidian Ciona intestinalis: prototypes with hybrid functionalities of vertebrate Toll-like receptors.
    Sasaki N; Ogasawara M; Sekiguchi T; Kusumoto S; Satake H
    J Biol Chem; 2009 Oct; 284(40):27336-43. PubMed ID: 19651780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes.
    Tian J; Guo X; Liu XM; Liu L; Weng QF; Dong SJ; Knowlton AA; Yuan WJ; Lin L
    Cardiovasc Res; 2013 Jun; 98(3):391-401. PubMed ID: 23447644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptors: new players in myocardial ischemia/reperfusion injury.
    Ha T; Liu L; Kelley J; Kao R; Williams D; Li C
    Antioxid Redox Signal; 2011 Oct; 15(7):1875-93. PubMed ID: 21091074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response.
    Boyd JH; Mathur S; Wang Y; Bateman RM; Walley KR
    Cardiovasc Res; 2006 Dec; 72(3):384-93. PubMed ID: 17054926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
    Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
    Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models.
    Patra MC; Achek A; Kim GY; Panneerselvam S; Shin HJ; Baek WY; Lee WH; Sung J; Jeong U; Cho EY; Kim W; Kim E; Suh CH; Choi S
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Yin and Yang of Toll-like receptors in cancer.
    Pradere JP; Dapito DH; Schwabe RF
    Oncogene; 2014 Jul; 33(27):3485-95. PubMed ID: 23934186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
    Federico S; Pozzetti L; Papa A; Carullo G; Gemma S; Butini S; Campiani G; Relitti N
    J Med Chem; 2020 Nov; 63(22):13466-13513. PubMed ID: 32845153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like Receptors from the Perspective of Cancer Treatment.
    Javaid N; Choi S
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important aspects of Toll-like receptors, ligands and their signaling pathways.
    Chang ZL
    Inflamm Res; 2010 Oct; 59(10):791-808. PubMed ID: 20593217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muramyl dipeptide activates human beta defensin 2 and pro-inflammatory mediators through Toll-like receptors and NLRP3 inflammasomes in human dental pulp cells.
    Lee SI; Kang SK; Jung HJ; Chun YH; Kwon YD; Kim EC
    Clin Oral Investig; 2015 Jul; 19(6):1419-28. PubMed ID: 25467233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.